CU6 Stock Overview A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteClarity Pharmaceuticals Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for Clarity Pharmaceuticals Historical stock prices Current Share Price AU$4.00 52 Week High AU$8.98 52 Week Low AU$1.80 Beta 1.69 1 Month Change -29.58% 3 Month Change -53.97% 1 Year Change 122.22% 3 Year Change 433.33% 5 Year Change n/a Change since IPO 166.67%
Recent News & Updates
Clarity Pharmaceuticals Ltd Expands its Pipeline with A Novel Optimised FAP-Targeted Radiopharmaceutical Dec 19
New minor risk - Profitability Dec 18
Forecast to breakeven in 2027 Dec 12
New minor risk - Profitability Nov 29
Forecast to breakeven in 2027 Nov 29
No longer forecast to breakeven Oct 18 See more updates
Clarity Pharmaceuticals Ltd Expands its Pipeline with A Novel Optimised FAP-Targeted Radiopharmaceutical Dec 19
New minor risk - Profitability Dec 18
Forecast to breakeven in 2027 Dec 12
New minor risk - Profitability Nov 29
Forecast to breakeven in 2027 Nov 29
No longer forecast to breakeven Oct 18
Clarity Pharmaceuticals Announces Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer Oct 14
MD, CEO & Executive Director exercised options to buy AU$8.3m worth of stock. Oct 06
We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth Sep 23
Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 20, 2024 Sep 23
Now 21% overvalued after recent price rise Sep 23
Clarity Pharmaceuticals Confirms the Appointment of Ms. Michelle Parker to Its Board, Effective September 20, 2024 Sep 20
Clarity Pharmaceuticals Ltd Receives FDA Fast Track Designation for 64Cu-Sar-Bispsma Aug 23
MD, CEO & Executive Director exercised options to buy AU$5.6m worth of stock. Aug 13
No longer forecast to breakeven Aug 07
Executive Chairman exercised options to buy AU$3.4m worth of stock. Aug 03
No longer forecast to breakeven Aug 03
No longer forecast to breakeven Jul 12
Price target increased by 14% to AU$3.87 May 16
New minor risk - Shareholder dilution Mar 29 Clarity Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 100.64532 million. Mar 29
Clarity Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 100.64532 million.
Non-Executive Director exercised options to buy AU$1.1m worth of stock. Mar 22
Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial Mar 16
Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range Mar 08
New major risk - Financial position Mar 02
Price target increased by 13% to AU$2.48 Jan 31
Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors Jan 16
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth Jan 03
Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA Dec 22
Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level Dec 01
Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer Nov 30
No longer forecast to breakeven Nov 30
Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE Nov 30
Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial Nov 08
Clarity Pharmaceuticals and PSI CRO AG Kick Off SAR-BispsMA Phase III Oct 28
Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 23, 2023 Oct 20
Clarity Pharmaceuticals Announces the Dosing of the First Patient in Its Theranostic (64) Cu Sar-Bombesin Phase I/Ii Trial in Metastatic Castrate Resistant Prostate Cancer Trial in Metastatic Castrates Resistant Prostate Cancer (Mcrpc) Oct 05
Price target increased by 8.5% to AU$1.82 Sep 08
New major risk - Revenue and earnings growth Aug 25
Clarity Pharmaceuticals Announces Successful Completion of Cohort 2 and Advancement to Cohort 2 of Theranostic Trial, Secure Aug 13
Clarity Pharmaceuticals Announces Phase II US-Based Diagnostic Cu SAR-Bombesin Jul 25
New minor risk - Profitability Jul 10
MD, CEO & Executive Director exercised options to buy AU$493k worth of stock. Jul 07
Clarity Pharmaceuticals Announces Positive Guidance from US FDA on Cu-64 Sar-Bispsma Phase III Trial in Prostate Cancer Jul 06
Consensus EPS estimates fall by 13% May 31
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow May 29
Consensus revenue estimates increase by 261% Mar 07
MD, CEO & Executive Director exercised options to buy AU$243k worth of stock. Feb 22
Clarity Pharmaceuticals Ltd Announces Its Phase II Diagnostic 64 Cu Sartate Trial (Disco NCT04438304) Feb 16
Clarity Pharmaceuticals Announces PROPELLER Trial Results - SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer Feb 15
Clarity Pharmaceuticals Ltd Announces Diagnostic Prostate Cancer Trial Reaches Recruitment Target Feb 09
Clarity Pharmaceuticals Ltd Announces Board Changes Feb 01
Clarity Pharmaceuticals Ltd Announces Positive Topline Results from SAR-bisPSMA Diagnostic Trial Dec 15
Price target increased to AU$1.54 Dec 08
Clarity Pharmaceuticals Announces IND Approval from the FDA for Theranostic Sar-Bombesin Trial in Prostate Cancer Nov 21
Less than half of directors are independent Nov 16
Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Phase II BOP Prostate Cancer Trial Nov 02
Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Prostate Cancer Trial Oct 28 Clarity Pharmaceuticals Ltd Announces First Patient Treated in Therapeutic Prostate Cancer Trial
Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 24, 2022 Oct 01
Consensus forecasts updated Sep 27
Clarity Pharmaceuticals Ltd Successfully Imaged Its First Participants in the Diagnostic 64 CU SAR-Bombesin Trial (Bop) for Patients with PSMA-Negative Prostate Cancer in Australia Sep 15
Clarity Pharmaceuticals Appoints Jeffrey Norenberg as Chief Scientific Officer Sep 13
Clarity Strengthens Protection of the SAR-bisPSMA Product with Granting of China Patent Sep 12
Clarity Pharmaceuticals Announces Recruitment Opens for Phase II Trial in Prostate Cancer Sep 05
Consensus revenue estimates increase by 182% Aug 31
Forecast to breakeven in 2025 Aug 25
Clarity Pharmaceuticals Ltd Advances to Cohort 3 of the Cl04 Trial of Sartate in Paediatric Neuroblastoma Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth Aug 24
Clarity Pharmaceuticals Announces Diagnostic 64 Cu SAR-Bombesin Trial (BOP) for Patients with Prostate Cancer Is Open for Recruitment in Australia Aug 22
Clarity Pharmaceuticals Announces Recruitment Complete for Diagnostic Prostate Cancer Trial Jul 20
Clarity Pharmaceuticals Ltd Appoints Louise Emmett to Its Scientific Advisory Board Jun 29
Non-Executive Director recently bought AU$53k worth of stock Jun 25
Clarity Pharmaceuticals Announces the Appointment of Rob Thomas, Non-Executive Director, to the Role of Lead Independent Director Jun 09
Clarity Pharmaceuticals Announces IND Approval by US FDA for Phase II SAR-Bombesin trial Jun 06
Non-Executive Director recently bought AU$58k worth of stock Jun 02
Neal Shore Joins Clarity Pharmaceuticals Ltd.'s Clinical Advisory Board May 27
Less than half of directors are independent Apr 27
Clarity Pharmaceuticals Ltd Announces Successfully Treats First Participant in the Diagnostic 64Cu SAR-bisPSMA trial Apr 22
Clarity Pharmaceuticals Successfully Treated Its First Participant in the Diagnostic Us-Based 64 Cu SAR-bisPSMA Trial for Patients with Biochemical Recurrence (BCR) of Prostate Cancer Apr 21
No longer forecast to breakeven Apr 20
Dr. Andrei Iagaru Joins Clarity's Scientific Advisory Board Apr 06
Clarity Pharmaceuticals Ltd Appoints David Green as Chief Financial Officer Apr 04
Clarity Pharmaceuticals Announces COBRA Trial in Prostate Cancer Opens for Recruitment Mar 29
Consensus forecasts updated Mar 07 Shareholder Returns CU6 AU Pharmaceuticals AU Market 7D -13.2% -6.9% -0.5% 1Y 122.2% -10.6% 8.2%
See full shareholder returns
Return vs Market: CU6 exceeded the Australian Market which returned 8.2% over the past year.
Price Volatility Is CU6's price volatile compared to industry and market? CU6 volatility CU6 Average Weekly Movement 10.1% Pharmaceuticals Industry Average Movement 10.3% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.7% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: CU6 has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CU6's weekly volatility (10%) has been stable over the past year.
About the Company Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
Show more Clarity Pharmaceuticals Ltd Fundamentals Summary How do Clarity Pharmaceuticals's earnings and revenue compare to its market cap? CU6 fundamental statistics Market cap AU$1.28b Earnings (TTM ) -AU$42.32m Revenue (TTM ) AU$11.51m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CU6 income statement (TTM ) Revenue AU$11.51m Cost of Revenue AU$0 Gross Profit AU$11.51m Other Expenses AU$53.83m Earnings -AU$42.32m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.13 Gross Margin 100.00% Net Profit Margin -367.83% Debt/Equity Ratio 0%
How did CU6 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 13:28 End of Day Share Price 2024/12/24 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Clarity Pharmaceuticals Ltd is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Hester Bell Potter Madeleine Williams Canaccord Genuity David Stanton Jefferies LLC
Show 3 more analysts